Search

Todd Aguilera MD PhD
Todd Aguilera MD PhD @aguilera_md ·
Proud of colleagues nationwide advancing work that truly matters for patients with #PDAC. Grateful to have Shelli, our RD at @UTSWCancer, so committed to patient care and contributing to @CanopyCancer through this effort.
171
Wungki Park, MD MS
Wungki Park, MD MS @CentralParkWMD ·
Replying to @CentralParkWMD
2/ KRAS G12D is virtually the most important☝️ RAS mutation in solid cancers 🧬KRAS mutations drive ~20% of cancers. 📊KRAS G12D alone drives: • 40% of pancreatic cancer #PDAC • 5% of #NSCLC • Also present in extrahepatic cholangiocarcinoma and gynecologic cancers For decades, this has been one of the hardest targets in oncology. @AnnaVarghese4 nature.com/articles/s4159… Lee et al. nature.com/articles/s4169…
2
4
2K
Targeted Oncology
Targeted Oncology @TargetedOnc ·
FDA agrees on Phase 3 design for zabilugene almadenorepvec in metastatic PDAC. VIRAGE Phase 2b showed median OS 10.8 vs 8.6 months (HR=0.57). Novel stroma-targeting oncolytic virus approach. Read more: hubs.li/Q048hKV50 #Oncology #PDAC
FDA Endorses Phase 3 Design for Oncolytic Virus in Metastatic PDAC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
FDA Endorses Phase 3 Design for Oncolytic Virus in Metastatic PDAC | Targeted Oncology - Immunoth...

FDA backs pivotal Phase 3 plan for VCN-01 plus chemo in metastatic pancreatic cancer, building on VIRAGE survival gains and adaptive dosing.

From targetedonc.com
183
Flavio G Rocha, MD, FACS, FSSO
Flavio G Rocha, MD, FACS, FSSO @FlavioRochaMD ·
What an inspirational story highlighting the strong bond of family and the impact of clinical trials for #PDAC Kudos to Dr. Adel Kardosh and GI medical oncology @OHSUKnight It is a privilege to work with this team #GiveCancerHell #wagehope @PanCAN @letswinpc @NatPancFdn
OHSU Knight Cancer Institute OHSU Knight Cancer Institute @OHSUKnight ·
Say was diagnosed with #PancreaticCancer in 2020, and her family directed her to OHSU for treatment. “That first meeting, they said they’re going to do everything they can to beat this. I was scared, feeling hopeless. They gave me hope.” - Tom, Say's son bit.ly/4sAlZyG
2
1.2K
mining Saudi Arabia
mining Saudi Arabia @ksamining ·
Interview with Stuart Smith, COO at SRK Consulting, recorded at #PDAC. He discusses the growing demand for critical minerals, new processing technologies, and why ESG readiness is key to securing mining investment. ▶️ Watch the interview lnkd.in/d8XKRFzt
15
mining Saudi Arabia
mining Saudi Arabia @ksamining ·
An interview with Jordan Quinn (Advisor, Athena Gold) recorded at #PDAC. He shares insights on drones in mineral exploration, AI in geological analysis, and Athena Gold’s upcoming 5,000-meter drill program at the Layered Lake project. Watch the interview bit.ly/4v6wYlh
28
Bassam Sonbol
Bassam Sonbol @sonbol_bassam ·
Such a low bar and still unfortunately missed! Hopefully such treatments will soon be obsolete with KRAS inhibitors! Fingers crossed! #kras #pdac
Nieves Martinez Lago MD PhD Nieves Martinez Lago MD PhD @DraMartinezLago ·
🧵 S-1 in 2L pancreatic cancer: still not changing practice (1/2) NAPAN trial 💊 Nal-IRI + S-1 vs nal-IRI + 5-FU/LV ❌ No benefit • PFS: 2.2 vs 3.3 mo • OS: 6.0 vs 9.1 mo 🔎 Confirms nal-IRI + 5-FU/LV as standard 🔗 ejcancer.com/article/S0959-… @OncoAlert @GrupoTTD
Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metasta...

This study aimed to determine the optimal second-line treatment strategy in patients with metastatic pancreatic cancer, hypothesizing that liposomal irinotecan (nal-IRI) combined with S-1 would be...

From ejcancer.com
1
2
1.1K